ABOUT US
We are an innovative biotechnology company focused on the development of new targeted therapies based on nanotechnology. We search for and develop new drug synergies in the treatment of diseases with unmet medical needs.
We are also rapidly advancing new products based on siRNA technology, which enables us to target entirely new therapeutic targets objectives. Our primary focus lies in oncology as the main goal of our activities.
Team BS Biotechna
Strategy
Searching for new synergies and new indications for known compounds to enhance efficiency and accelerate the development path of new drugs, reducing associated risks and costs.
We have more than 20 confirmed high-efficacy synergies in over 10 types of cancer, including breast, lung, and brain tumors, for which we have developed a nanoparticle platform.
Developing innovative RNA and DNA-based products for new targets in cancer treatment.
Our delivery system ensures the stability of nucleic acids and effective delivery.
Developing our proprietary nanoparticle platform for the delivery of nucleic acids and small molecules
Advancing nanotechnology is a particular area of interest. Leveraging our knowledge and experience, we are developing our own structures with various physicochemical properties, aiming to deliver multiple synergistic drugs with the goal of overcoming adaptive resistance. This serves as a foundation for enhancing effectiveness and reducing toxicity beyond the treatment target.We possess the capability to create a nanoparticle platform with a wide range of flexibility, allowing us to diversify our portfolio focused on oncology and its unmet medical needs. This includes cancers such as small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sarcomas, urothelial carcinoma, pancreatic adenocarcinoma, ovarian cancer, and more.